Formulation Development
Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial
Clementia Pharmaceuticals Inc.recently announced the early completion of patient enrollment in the MOVE Trial, Clementia’s registrational Phase 3 clinical study evaluating the safety and efficacy of palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP).
MilliporeSigma & InnoCore Pharmaceuticals to Improve Patient Compliance With New Drug Delivery Technology
MilliporeSigma and InnoCore Pharmaceuticals; Groningen, Netherlands, have recently entered into a global cooperation agreement to provide InnoCore’s proprietary SynBiosys biodegradable polymer platform. The drug delivery…
Aegis’ Expands International & US Intravail Patent Portfolio on Multiple Fronts
Aegis Therapeutics LLC recently announced it has been awarded European Patent No. EP2381773(B1) and Canadian Patent No. 2,748,268, providing fast- acting formulations for triptans, a…
International Stem Cell Corporation Developed 3D Liver Structures
International Stem Cell Corporation recently announced that ISCO’s Research and Development team has developed novel methods that efficiently generate human 3D liver-like tissue. According to…
Innovest Global Signs Worldwide Agreement With Cedars-Sinai Medical Center to Commercialize Vaccine
StemVax Therapeutics, an Innovest Global Inc. holding, has been awarded an exclusive worldwide license agreement from Cedars-Sinai Medical Center in Los Angeles, CA, for all…
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement to Advance AAV Gene Therapy Technology
Fortress Biotech recently announced that its subsidiary, Aevitas Therapeutics, Inc. has entered into a sponsored research agreement (SRA) with the laboratory of Wenchao Song, PhD,…
Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Delivery
Therapeutics Solutions International, Inc. recently announced successful production of a stable microemulsion of Alpha Lipoic Acid (ALA) from ingredients Generally Regarded as Safe (GRAS). The…
Avalon GloboCare Forms Strategic Partnership With Weill Cornell Medical College to Co-develop Technologies & Bio-production of CAR-T Therapy
This strategic partnership aims to co-develop bio-production and standardization procedures in procurement, storage, processing, clinical study protocols, and bio-banking for Chimeric Antigen Receptor (CAR)-T therapy, in accordance with the Foundation of Accreditation for Cellular Therapy (FACT) and American Association of Blood Banks (AABB) standards.
Vasomune Therapeutics & AnGes, Inc. Enter Multi-Million Dollar Global Co-Development Agreement
Vasomune Therapeutics and AnGes, Inc. recently announced the signing of an innovative global co-development agreement for the development and commercialization of therapeutics treating diseases associated…
Cantabio Pharmaceuticals to Present Positive In Vivo Efficacy Results
Cantabio Pharmaceuticals Inc. recently announced that Dr. Gergely Toth, Cantabio's CEO, will present results from the company's DJ-1 protein targeting small molecule pharmacological chaperone therapeutic…
Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066
Moleculin Biotech, Inc. recently announced enrollment has opened for a physician-sponsored clinical trial of WP1066 for the treatment of glioblastoma and brain metastases in adults.…
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA
ARCA Biopharma, Inc. recently announced it has received guidance from the US FDA following an End-of-Phase 2 meeting regarding the Phase 3 program for ARCA’s…
BioPharmX Receives IRB Approval to Initiate Phase 2 Trial
BioPharmX Corporation recently announced it has received Institutional Review Board approval for its Phase 2 study of BPX-04 for the treatment of papulopustular rosacea. The…
Translate Bio Announces Closing of Collaboration & Licensing Agreement with Sanofi Pasteur
Translate Bio recently announced the closing of a previously announced research collaboration and licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to…
WuXi Biologics & Immune Pharmaceuticals Announce Late-Phase Development & Manufacturing Partnership
WuXi Biologics and Immune Pharmaceuticals recently announced a development and manufacturing agreement for the production of bertilimumab, Immune’s first-in-class anti-eotaxin-1 monoclonal antibody. Bertilimumab is designed…
FDA Grants Fast-Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor
Aclaris Therapeutics, Inc. recently announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Aclaris’ investigational topical Janus Kinase (JAK) 1/3…
Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination With FluMist Influenza Vaccine
Hemispherx Biopharma, Inc. recently announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen in combination with FluMist…
Aurin Biotech Awarded US Patent for Cancer Drug
Aurin Biotech’s ATAC, a drug which has successfully halted the growth of cancerous tumors, was recently awarded a patent (10,004,707 B2) by the United States…
Catalent Biologics Adopts Berkeley Lights’ Beacon Optofluidic Platform
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, and Berkeley Lights, Inc.…
Axovant Announces Global Licensing Agreement With Benitec Biopharma
Axovant Sciences recently announced it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal…
